Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avonex was produced by Biogen Idec.

Elan hit by 'disaster' withdrawal

Both patients were involved in a trial that examined the effectiveness of Tysabri in combination with Biogen's existing MS drug, Avonex, on the market for nearly nine years.

Analysts back Tysabri return despite FDA concern

Tysabri was withdrawn a year ago after two patients taking it in combination with another Biogen MS drug, Avonex, developed a rare and often fatal brain infection known as progressive multifocal

Lectus wins USD 6.1m investment from Wellcome Trust

It is the fifth largest segment of the CNS market. The MS market is currently dominated by six treatments: Avonex (Biogen), Betaseron/Betaferon (Schering), Copaxone (Teva), Novatrone (Schering), Rebif (Serono/ Pfizer)

New accounts: May

Grandma Vines. Dermatology (consumer). hsdcommunications. Biogen Idec. Avonex. CNS. TVF Communications.

PM Society Award Winners 2006

Craft Award:Detailing Aid. Winner:Seven Stones for Avonex. Sponsor: Ashfield Healthcare. Craft Award:GP Direct Mail Campaign. ... Sponsor:Wiley Pharmafile. Craft Award:Hospital Campaign. Winner:Seven Stones for Avonex. Sponsor: TNS Healthcare.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...